The learning framework
The gap between working and shippable
A technology works in the laboratory. The data is real, the effect is genuine, and everyone who sees it understands why it matters. What follows is not one step but a sequence of gates, each of which costs money and produces evidence rather than revenue. The prototype has to become a controlled design. The design has to be shown to perform reliably outside the hands that built it. It has to be made repeatedly to a standard, at a cost that leaves room for a business. Somewhere in that sequence the company runs out of money and raises again, and the terms of that raise are set by which gate it has cleared. Founders who have only seen the laboratory end tend to treat this as engineering that follows the science. It is engineering, and it is also the part of the company's life where most of the capital is spent and most of the ownership changes hands.
Why the gates are read as schedule rather than as capital
Development plans are built as timelines. Gates appear as dates, and dates create the impression that the sequence is about duration. What a gate actually does is convert money into evidence, and the evidence is what allows the next financing to happen at a higher price than the last one. Two errors follow from reading gates as dates. Founders raise against a calendar rather than against a milestone, which means arriving at an investor conversation with time elapsed instead of risk retired. And they underestimate the gates that produce no visible progress, particularly the transition from something that works to something that can be made repeatedly, which consumes capital while the product appears unchanged. The device path and the therapeutic path diverge sharply here. A device team faces design freeze, verification, and a manufacturing transition. A therapeutic team faces a clinical program and a manufacturing problem of an entirely different kind. The capital profiles are not comparable and neither are the failure modes, which is why this evolution splits rather than generalizing.
Development read as a capital plan
Healthcare innovators who complete this evolution can lay out the gates between where they are and a commercial product, cost each one, and identify which ones retire risk that an investor prices. They raise against milestones rather than against months. They understand which gate their own technology is most likely to fail at, and they know the failure modes specific to their path, because they have taken the track that matches their product rather than a general treatment of both.
By the end of this evolution, you will be able to:
Map the gates between prototype and product
Lay out the full sequence for your technology, from where it is now to something a patient can receive. Understand what each gate demands in evidence, capital, and time, and which ones cannot be run in parallel.
Treat a gate as a financing event
Understand that a milestone matters commercially because it retires a risk an investor is pricing. Learn which gates change what a company is worth and which merely consume capital, and why raising against a date rather than a milestone weakens your position.
Recognize the gates that consume capital invisibly
Identify the stages where a great deal of money is spent and nothing appears to change: the transition from something that works to something that can be made repeatedly and to a standard. Understand why these stages surprise founders and how to plan for them.
Compare the device and therapeutic paths
Understand how the two routes to the bedside differ in capital profile, timeline, and failure mode, so that you can read a plan on either side and know why a partner, an acquirer, or an investor from the other world sees your risk differently.
Why this matters
Recommended for
Healthcare innovators navigating:
Choose your path
Bench to Bedside: Medical Devices
Prototype to commercial device. Stage-gate development as a capital structure issue, the design freeze decision, the GMP transition, and the manufacturing decisions that shape unit economics and acquirability. Includes device pivotal study structure.
Explore →Bench to Bedside: Therapeutics
Preclinical candidate to commercial therapy across drugs, biologics, and cell and gene therapies. IND strategy as a capital decision, CDMO selection, CMC milestones as funding triggers, and the scale-up gap between clinical success and commercial supply. Includes clinical program structure.
Explore →Required: one of the two. Both are available at no additional charge.
Faculty who understand the process move through it faster.
Academic medical centers, research universities, and health systems sponsor cohorts so that inventors arrive at the office of technology transfer prepared: complete disclosures, clean assignment records, and realistic expectations about pathway and timeline. Cohort training is available for faculty, residents, and research staff, with CME.
Learn more about institutional cohorts →How to get started
Your path to becoming a Certified Professional Entrepreneur
Reserve your seat
Your deposit reserves a place in the cohort. Twenty seats. No application, no admissions committee, no waiting on a decision.
Begin the evolutions
Structured online learning you work through on your own schedule. Lectures run under fifteen minutes. Each evolution carries reading, supporting material, working tools, and case studies drawn from real transactions.
Join the live sessions
Live discussion sessions on Zoom, facilitated by Chris and Christos. Not recorded. This is where the material meets your actual situation, and where the cohort becomes a network.
Continue your structural training
Answers that help you decide with confidence
A laboratory result is not a product, and the distance between them is measured in capital.